GlyCardial Diagnostics receives the EmprendedorXXI Award in Catalonia Blog Post

The companies GlyCardial Diagnostics, based in the Barcelona Science Park, and Mitiga Solutions, have been honoured with the EmprendedorXXI Award in Catalonia, which is promoted by CaixaBank –through DayOne, its specialized division that provides banking services for technology and innovation companies and its investors- and awarded jointly by the Ministry of Industry, Commerce and Tourism, through Empresa Nacional de Innovación, S.A. (ENISA). The award ceremony was held yesterday in the Recinte Modernista of the Hospital de Sant Pau as part of the ‘DayOne Innovation Summit’ event. Outside of the regional prize, next May 14th the sectorial EntrepreneurXXI Awards will be awarded to 6 nationwide companies with the highest growth potential in their sector.

 

Bionure reports successful Phase 1 Study for lead candidate BN201 Blog Post

Bionure, a biotech company specialized in neuroprotection based in the Barcelona Science Park, today announces that it has successfully concluded its Phase 1 clinical study with its lead candidate BN201, a first-in-class compound to treat neurodegenerative diseases such as Multiple Sclerosis (MS). The company is now preparing a Series B funding round to finance the Phase 2 clinical program. 

 

Defective glial cells can push neurons toward Parkinson’s disease Blog Post

Defective versions of human brain cells called astrocytes are linked to the buildup of a toxic protein that is one the hallmarks of Parkinson’s disease. This is one of the main conclusions of a study led by Antonella Consiglio, researcher at the Institute of Biomedicine of the University of Barcelona (IBUB) in the Barcelona Science Park, and the Bellvitge Biomedical Research Institute (IDIBELL), and Àngel Raya, from the Center of Regenerative Medicine in Barcelona (CMR[B]-IDIBELL).

 

UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs Blog Post

The Unit of Experimental Toxicology and Ecotoxicology of the Barcelona Science Park (PCB) is taking part in a consortium that aims to develop and provide preclinical checks for new candidates for first-in-class cancer drugs. The project, called Preclinonco, has just received an injection of nearly 350,000 euros from the Retos-Colaboración 2017 program, promoted by the Ministry of Science, Innovation and Universities with ERDF funding.

 

ICCUB becomes a Scientifica International technological partner Blog Post

The Institute of Cosmos Sciences (ICCUB) of the University of Barcelona has signed an agreement with the company Scientifica International to work together in the fields of nuclear and particle physics, space sciences and industry. One of the first licensed products for its trade is the Multi-purpose Integrated Circuit (eMUSIC), carried out at the ICCUB technology Unit (ICCUB-TECH), based in the Barcelona Science Park.

 

SOM Biotech initiates of Phase 2a clinical trial of SOM3355 in Huntington’s disease patients Blog Post

SOM Biotech, a clinical-stage biopharmaceutical company –with headquarters in Barcelona Science Park– that discovers and develops drugs for orphan indications in the central nervous system,  has initiated of Phase 2a clinical trial of its compound SOM3355 for the treatment of the chorea movements associated to Huntington’s disease. The investigational product is a repositioned drug, currently commercialized for the treatment of hypertension. 

 

The call for the 2018-2019 Research in Society program is open Blog Post

Today, Monday 2 July, the Barcelona Science Park (PCB) has kicked off its 18th Research in Society programme with the opening of the pre-registration period for the experimental workshops “Discover research!” and “Do research!”. Places will be allocated to applicant schools in a draw using the list of reservation numbers.

 

Jaume Amat, CEO of Specipig, new president of CataloniaBio & HealthTech Blog Post

CataloniaBio & HealthTech has chosen its first president and board of directors today, after the merger of the CataloniaBio association of companies and the HealthTech Cluster last December, at an extraordinary members’ assembly. The new entity, located at the Barcelona Science Park, represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine.

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).